{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T06:29:04Z","timestamp":1775024944656,"version":"3.50.1"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease with limited disease-modifying therapies and a poor overall prognosis. Statins, are commonly used for dyslipidemia, and have been proposed to exert cholesterol-independent actions including anti-inflammatory and potential neuroprotective effects. Prior studies, However, existing studies offer conflicting results regarding their impact on ALS survival. This systematic review and meta-analysis aimed to evaluate the association between statin use and survival outcomes in patients with ALS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive literature search was conducted in PubMed, Scopus, and Web of Science from inception to September 2025. Studies were included if they reported survival outcomes for statin users vs. non-users among patients with ALS. Data on hazard ratios (HRs) were extracted and pooled using fixed- or random-effects models, depending on heterogeneity. Meta-regression and sensitivity analyses were performed to explore the influence of covariates such as age and gender.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Six studies with 3,739 participants (889 statin users) met the inclusion criteria. The pooled analysis showed no statistical significant association between statin use and ALS survival [Log(HR) = \u22120.04; 95% CI: \u22120.18 to 0.10], with moderate heterogeneity (\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      = 24.85%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The pooled estimate in this meta-analysis did not show a statistically significant association between statin use and ALS survival; however, the evidence is limited by heterogeneity in statin exposure definitions and likely residual confounding in predominantly observational data. Further high-quality studies with large sample sizes are needed to determine whether specific subgroups may benefit\/harm from statin therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420251160344<\/jats:ext-link>\n                      ; PROSPERO: CRD420251160344.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2026.1753992","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T04:27:25Z","timestamp":1775017645000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The effect of statins on the survival of patients with amyotrophic lateral sclerosis: a meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Hui","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Pharmacy, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/S0140-6736(22)01272-7","article-title":"Amyotrophic lateral sclerosis","volume":"400","author":"Feldman","year":"2022","journal-title":"Lancet."},{"key":"B2","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3109\/17482960802566824","article-title":"Prognostic factors in ALS: a critical review","volume":"10","author":"Chio","year":"2009","journal-title":"Amyotroph Lateral Scler."},{"key":"B3","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1002\/med.21528","article-title":"Riluzole and edaravone: a tale of two amyotrophic lateral sclerosis drugs","volume":"39","author":"Jaiswal","year":"2019","journal-title":"Med Res Rev."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2976","DOI":"10.36922\/bh.2976","article-title":"In silico investigation of lipid-based compounds implicated in amyotrophic lateral sclerosis","volume":"2","author":"Fatoki","year":"2024","journal-title":"Brain Heart"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.3390\/molecules26102838","article-title":"The effects of statins on neurotransmission and their neuroprotective role in neurological and psychiatric disorders","volume":"26","author":"Kosowski","year":"2021","journal-title":"Molecules."},{"key":"B6","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s00210-016-1252-4","article-title":"Pleiotropic effects of statins: new therapeutic targets in drug design","volume":"389","author":"Bedi","year":"2016","journal-title":"Naunyn Schmiedebergs Arch Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jns.2008.06.022","article-title":"Influence of statins treatment on survival in patients with amyotrophic lateral sclerosis","volume":"273","author":"Drory","year":"2008","journal-title":"J Neurol Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1007\/s00415-014-7445-1","article-title":"Prior medical conditions and the risk of amyotrophic lateral sclerosis","volume":"261","author":"Seelen","year":"2014","journal-title":"J Neurol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1080\/17482960802163614","article-title":"Medications and laboratory parameters as prognostic factors in amyotrophic lateral sclerosis","volume":"9","author":"Qureshi","year":"2008","journal-title":"Amyotroph Lateral Scler."},{"key":"B10","doi-asserted-by":"publisher","first-page":"515","DOI":"10.2165\/00002018-200730060-00005","article-title":"Statins, neuromuscular degenerative disease and an amyotrophic lateral sclerosis-like syndrome: an analysis of individual case safety reports from vigibase","volume":"30","author":"Edwards","year":"2007","journal-title":"Drug Safety."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1093\/aje\/kwac054","article-title":"Statin medications and amyotrophic lateral sclerosis incidence and mortality","volume":"191","author":"Weisskopf","year":"2022","journal-title":"Am J Epidemiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s40264-022-01184-1","article-title":"Amyotrophic lateral sclerosis as an adverse drug reaction: a disproportionality analysis of the food and drug administration adverse event reporting system","volume":"45","author":"Gaimari","year":"2022","journal-title":"Drug Saf."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1212\/01.wnl.0000285080.70324.27","article-title":"Dyslipidemia is a protective factor in amyotrophic lateral sclerosis","volume":"70","author":"Dupuis","year":"2008","journal-title":"Neurology."},{"key":"B14","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1093\/hmg\/ddy384","article-title":"Causal effects of blood lipids on amyotrophic lateral sclerosis: a mendelian randomization study","volume":"28","author":"Zeng","year":"2018","journal-title":"Hum Mol Genet."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e1062","DOI":"10.1212\/WNL.0000000000201657","article-title":"Association between serum lipids and survival in patients with amyotrophic lateral sclerosis: a meta-analysis and population-based study","volume":"100","author":"Janse van Mantgem","year":"2023","journal-title":"Neurology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B17","unstructured":"Wells\n              GA\n            \n            \n              Shea\n              B\n            \n            \n              O'Connell\n              D\n            \n            \n              Peterson\n              J\n            \n            \n              Welch\n              V\n            \n            \n              Losos\n              M\n            \n          \n          The Newcastle-Ottawa Scale (NOS) for Assessing the Quality if Nonrandomized Studies in Meta-analyses"},{"key":"B18","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.otohns.2010.05.007","article-title":"A practical guide to understanding Kaplan-Meier curves","volume":"143","author":"Rich","year":"2010","journal-title":"Otolaryngol Head Neck Surg."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1111\/ene.14393","article-title":"Amyotrophic lateral sclerosis: a clinical review","volume":"27","author":"Masrori","year":"2020","journal-title":"Eur J Neurol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1080\/17460441.2025.2474661","article-title":"Drug repurposing in amyotrophic lateral sclerosis (ALS)","volume":"20","author":"Carroll","year":"2025","journal-title":"Expert Opin Drug Discov."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1111\/ene.14300","article-title":"Statins, diabetes mellitus and prognosis of amyotrophic lateral sclerosis: data from 501 patients of a population-based registry in southwest Germany","volume":"27","author":"Schumacher","year":"2020","journal-title":"Eur J Neurol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e70095","DOI":"10.1111\/ene.70095","article-title":"Statin use and amyotrophic lateral sclerosis survival: a population-based cohort study","volume":"32","author":"Vaage","year":"2025","journal-title":"Eur J Neurol."},{"key":"B23","volume-title":"Statistical Methods in Cancer Research Volume V: Bias Assessment in Case-Control and Cohort Studies for Hazard Identification","author":"De Gonz\u00e1lez","year":"2024"},{"key":"B24","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3109\/21678421.2012.732078","article-title":"Statins and amyotrophic lateral sclerosis: a systematic review and meta-analysis","volume":"14","author":"Zheng","year":"2013","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e26751","DOI":"10.1097\/MD.0000000000026751","article-title":"Relationship between statins and the risk of amyotrophic lateral sclerosis: a PRISMA-compliant meta-analysis","volume":"100","author":"Chang","year":"2021","journal-title":"Medicine."},{"key":"B26","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s13760-021-01753-8","article-title":"Statins and risk of amyotrophic lateral sclerosis: a systematic review and meta-analysis","volume":"122","author":"Nabizadeh","year":"2022","journal-title":"Acta Neurol Belg."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.64898\/2025.12.23.25342802","article-title":"Statin use and risk of amyotrophic lateral sclerosis: an active-comparator, new-user cohort study","author":"Okada","year":"2025","journal-title":"medRxiv"},{"key":"B28","doi-asserted-by":"publisher","first-page":"7688","DOI":"10.1111\/febs.16175","article-title":"Cholesterol dyshomeostasis in amyotrophic lateral sclerosis: cause, consequence, or epiphenomenon?","volume":"289","author":"Hartmann","year":"2022","journal-title":"FEBS J."},{"key":"B29","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/jnc.15228","article-title":"24S-hydroxycholesterol: cellular effects and variations in brain diseases","volume":"157","author":"Sodero","year":"2021","journal-title":"J Neurochem."},{"key":"B30","doi-asserted-by":"publisher","first-page":"567753","DOI":"10.3389\/fneur.2020.567753","article-title":"Lipid profile in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis","volume":"11","author":"Liu","year":"2020","journal-title":"Front Neurol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1111\/1471-0528.15199","article-title":"Randomised controlled trials - the gold standard for effectiveness research: study design: randomised controlled trials","volume":"125","author":"Hariton","year":"2018","journal-title":"BJOG."},{"key":"B32","doi-asserted-by":"publisher","first-page":"687585","DOI":"10.3389\/fcvm.2021.687585","article-title":"Hydrophilic or lipophilic statins?","volume":"8","author":"Climent","year":"2021","journal-title":"Front Cardiovasc Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1253\/circj.CJ-10-0110","article-title":"Pleiotropic effects of statins","volume":"74","author":"Zhou","year":"2010","journal-title":"Circ J"},{"key":"B34","doi-asserted-by":"publisher","first-page":"858","DOI":"10.7326\/0003-4819-150-12-200906160-00009","article-title":"Narrative review: statin-related myopathy","volume":"150","author":"Joy","year":"2009","journal-title":"Ann Intern Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/biof.1597","article-title":"The effects of statins on microglial cells to protect against neurodegenerative disorders: a mechanistic review","volume":"46","author":"Bagheri","year":"2020","journal-title":"Biofactors."},{"key":"B36","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s12035-014-9030-0","article-title":"Atorvastatin protects NSC-34 motor neurons against oxidative stress by activating PI3K, ERK and free radical scavenging","volume":"53","author":"Lee","year":"2016","journal-title":"Mol Neurobiol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/qjmed\/hcp093","article-title":"Statin therapy, muscle function and falls risk in community-dwelling older adults","volume":"102","author":"Scott","year":"2009","journal-title":"QJM."},{"key":"B38","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1097\/JES.0b013e31826c169e","article-title":"Effect of statins on skeletal muscle: exercise, myopathy, and muscle outcomes","volume":"40","author":"Parker","year":"2012","journal-title":"Exerc Sport Sci Rev."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1753992\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T04:27:31Z","timestamp":1775017651000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1753992\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":38,"alternative-id":["10.3389\/fneur.2026.1753992"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1753992","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"article-number":"1753992"}}